XML 28 R50.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaborative Research Development and License Agreements - Additional Information (Detail) (USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2014 Workers | Dec. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2011 | Dec. 31, 2008 | Dec. 31, 2012 | Mar. 31, 2012 | Oct. 31, 2011 | Sep. 30, 2006 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2008 | Sep. 30, 2013 | Jun. 30, 2012 | May 31, 2012 | Jul. 31, 2011 | Aug. 31, 2010
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of healthy workers placebo was delivered by inhalation | 45 dvax_NumberOfHealthyWorkersPlaceboWasDeliveredByInhalation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of doses well tolerated |  |  |  | 15.4 mg/week |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional revenue recognized |  |  |  | $ 1,100,000 us-gaap_DeferredRevenueRevenueRecognized |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from milestone payment |  | 8,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized | 5,400,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized |  | 3,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 2,500,000 us-gaap_DeferredRevenue |  |  |  |  |  |  |
National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable | 200,000 us-gaap_GrantsReceivable / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Glaxo Smith Kline |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Revenue |  |  |  |  |  | 10,000,000 us-gaap_ProceedsFromCollaborators / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_GlaxoSmithKlineMember |  |  |  |  |  |  |  |  |  |  |  |
Hepatic Fibrosis and Cirrhosis | National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepaticFibrosisAndCirrhosisMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |  |  |  |
Autoimmune Disease | National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_AutoimmuneDiseaseMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |  |  |
Rheumatoid Arthritis | National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_RheumatoidArthritisMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |  |
Skin Autoimmune Inflammation | National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 us-gaap_GrantsReceivable / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_SkinAutoimmuneInflammationMember / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |
Amendment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Revenue |  | 8,000,000 us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember | 5,400,000 us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amendment | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional revenue recognized |  |  |  | 100,000,000 us-gaap_DeferredRevenueRevenueRecognized / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amendment | Advance the program following completion of Phase 2a |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Revenue |  |  |  |  |  |  | 6,000,000 us-gaap_ProceedsFromCollaborators / us-gaap_ContingentConsiderationByTypeAxis = dvax_ContingentConsiderationMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember | 2,600,000 us-gaap_ProceedsFromCollaborators / us-gaap_ContingentConsiderationByTypeAxis = dvax_ContingentConsiderationMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember |  |  |  |  |  |  |  |  |  |
Astra Zeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration and license agreement period |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |
Collaboration Revenue |  |  |  |  |  |  |  |  | 3,000,000 us-gaap_ProceedsFromCollaborators / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |  |  |  |  |  |  |
Deferred revenue recognition period |  | 30 months | 48 months |  | 74 months |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from milestone payment |  |  |  | 2,174,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |  |  |  |  | 2,507,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 2,462,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |  |  |  |
Deferred revenue |  | 12,800,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  | 12,800,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |  |  |  |  | 4,800,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |  |  |  |  |
National Institute Of Allergy And Infectious Diseases | Hepatitis B Virus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,400,000 us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepatitisBVirusMember
National Institute Of Allergy And Infectious Diseases | Iss Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration and license agreement period |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,000,000 us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_IssTechnologyMember |  |  |  |  |

X
- Definition Description of doses well tolerated. + References No definition available. + Details
Name: | dvax_DescriptionOfDosesWellTolerated
Namespace Prefix: | dvax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of healthy workers placebo was delivered by inhalation. + References No definition available. + Details
Name: | dvax_NumberOfHealthyWorkersPlaceboWasDeliveredByInhalation
Namespace Prefix: | dvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research collaboration and license agreement period. + References No definition available. + Details
Name: | dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognition period. + References No definition available. + Details
Name: | dvax_RevenueRecognitionPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_AutoimmuneDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_HepaticFibrosisAndCirrhosisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_RheumatoidArthritisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_SkinAutoimmuneInflammationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=dvax_AmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |